Clinical value of botulinum toxin in neurological indications, European Journal of Neurology, vol.6, issue.4, pp.20-26, 2006. ,
DOI : 10.1046/j.1468-1331.2001.00040.x
Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke, New England Journal of Medicine, vol.347, issue.6, pp.395-400, 2002. ,
DOI : 10.1056/NEJMoa011892
Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A, NeuroToxicology, vol.26, issue.5, pp.785-93, 2005. ,
DOI : 10.1016/j.neuro.2005.01.017
Neurobiological basis for the use of botulinum toxin in pain therapy, Journal of Neurology, vol.251, issue.0, pp.1-7, 2004. ,
DOI : 10.1007/s00415-004-1102-z
Chapter 3 Nociceptors: neurogenic inflammation, Handbook of clinical neurology Pain, F, vol.81, pp.23-33, 2006. ,
DOI : 10.1016/S0072-9752(06)80007-2
Presynaptic Effects of Botulinum Toxin Type A on the Neuronally Evoked Response of Albino and Pigmented Rabbit Iris Sphincter and Dilator Muscles, Japanese Journal of Ophthalmology, vol.44, issue.2, pp.106-115, 2000. ,
DOI : 10.1016/S0021-5155(99)00197-5
Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms, Biochemical Pharmacology, vol.59, issue.11, pp.1403-1406, 2000. ,
DOI : 10.1016/S0006-2952(00)00260-4
Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin, Pfl??gers Archiv European Journal of Physiology, vol.8, issue.2, pp.297-305, 1996. ,
DOI : 10.1007/BF02346386
Regulation of Calcitonin Gene-Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy, Headache: The Journal of Head and Face Pain, vol.19, issue.suppl 1, pp.35-42, 2004. ,
DOI : 10.1111/j.1526-4610.2004.04007.x
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain, Pain, vol.107, issue.1, pp.125-133, 2004. ,
DOI : 10.1016/j.pain.2003.10.008
Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity, Journal of Biological Chemistry, vol.279, issue.24, pp.25665-25672, 2004. ,
DOI : 10.1074/jbc.M311515200
Botulinum neurotoxins and formalin-induced pain: Central vs. peripheral effects in mice, Brain Research, vol.1082, issue.1, pp.124-131, 2006. ,
DOI : 10.1016/j.brainres.2006.01.117
Botulinum toxin type A in experimental neuropathic pain, Journal of Neural Transmission, vol.112, issue.2, pp.215-224, 2005. ,
DOI : 10.1007/s00702-004-0265-1
Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain, Neuroscience, vol.145, issue.1, pp.1-4, 2007. ,
DOI : 10.1016/j.neuroscience.2006.12.004
Les effets de la toxine botulique a sur ??allodynie m??canique et ??allodynie au froid chez un mod??le de douleur neuropathique chez le rat, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.43, issue.1, pp.470-77, 2006. ,
DOI : 10.1007/BF03022619
CHRONIC HYPERALGESIA AND SKIN WARMING CAUSED BY SENSITIZED C NOCICEPTORS, Brain, vol.112, issue.3, pp.621-668, 1989. ,
DOI : 10.1093/brain/112.3.621
Postherpetic Neuralgia: Irritable Nociceptors and Deafferentation, Neurobiology of Disease, vol.5, issue.4, pp.209-236, 1998. ,
DOI : 10.1006/nbdi.1998.0204
Capsaicin evoked pain and allodynia in post-herpetic neuralgia, Pain, vol.88, issue.2, pp.125-158, 2000. ,
DOI : 10.1016/S0304-3959(00)00311-0
Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review, PLoS Medicine, vol.2, issue.7, p.164, 2005. ,
DOI : 10.1371/journal.pmed.0020164.t502
Persistent postsurgical pain: risk factors and prevention, The Lancet, vol.367, issue.9522, pp.1618-1643, 2006. ,
DOI : 10.1016/S0140-6736(06)68700-X
EFNS guidelines on pharmacological treatment of neuropathic pain, European Journal of Neurology, vol.32, issue.2, pp.1153-69, 2006. ,
DOI : 10.1053/eujp.2001.0316
Algorithm for neuropathic pain treatment: An evidence based proposal, Pain, vol.118, issue.3, pp.289-305, 2005. ,
DOI : 10.1016/j.pain.2005.08.013
Epidemiology and treatment of neuropathic pain: The UK primary care perspective, Pain, vol.122, issue.1, pp.156-62, 2006. ,
DOI : 10.1016/j.pain.2006.01.030
A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain, The Clinical Journal of Pain, vol.18, issue.Supplement, pp.177-81, 2002. ,
DOI : 10.1097/00002508-200211001-00010
Subcutaneous BTX-A in the treatment of neuropathic pain: a pilot study. Presented at the 38th Interagency Botulism Research Coordinating meeting, pp.292356-292357, 2001. ,
Botulinum Toxin A Improved Burning Pain and Allodynia in Two Patients With Spinal Cord Pathology, Pain Medicine, vol.4, issue.2, pp.206-210, 2003. ,
DOI : 10.1046/j.1526-4637.2003.03013.x
Botulinum Toxin A Relieved Neuropathic Pain in a Case of Post-Herpetic Neuralgia, Pain Medicine, vol.7, issue.1, pp.89-91, 2006. ,
DOI : 10.1111/j.1526-4637.2006.00100.x
Botulinum toxin for palmar hyperhidrosis, The Lancet, vol.349, issue.9047, p.252, 1997. ,
DOI : 10.1016/S0140-6736(05)64861-1
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response, Neurology, vol.62, issue.2, pp.218-243, 2004. ,
DOI : 10.1212/01.WNL.0000103237.62009.77
A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain, Neurology, vol.59, issue.11, pp.1694-700, 2002. ,
DOI : 10.1212/01.WNL.0000036273.98213.34
Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, vol.23, pp.129-167, 1994. ,
Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia, Brain, vol.129, issue.4, pp.129-963, 2006. ,
DOI : 10.1093/brain/awl016
Development and validation of the Neuropathic Pain Symptom Inventory, Development and validation of the Neuropathic Pain Symptom Inventory, pp.248-57, 2004. ,
DOI : 10.1016/j.pain.2003.12.024
The Hospital Anxiety and Depression Scale, Acta Psychiatrica Scandinavica, vol.141, issue.6, pp.361-70, 1983. ,
DOI : 10.1111/j.1600-0447.1983.tb09716.x
The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization, Pain, vol.122, issue.3, pp.315-340, 2006. ,
DOI : 10.1016/j.pain.2006.04.014
Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin, Pain, vol.130, issue.1, pp.76-83, 2007. ,
DOI : 10.1016/j.pain.2006.10.030
Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study, Journal of the Neurological Sciences, vol.205, issue.1, pp.59-63, 2002. ,
DOI : 10.1016/S0022-510X(02)00313-1
Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin, Journal of Neurology, vol.250, issue.2, pp.188-193, 2003. ,
DOI : 10.1007/s00415-003-0971-x
Botulinum toxin A does not alter capsaicin-induced pain perception in human skin, Journal of the Neurological Sciences, vol.260, issue.1-2, pp.38-42, 2007. ,
DOI : 10.1016/j.jns.2007.03.023
A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model, Anesthesia & Analgesia, vol.102, issue.2, pp.509-525, 2006. ,
DOI : 10.1213/01.ane.0000194447.46763.73
A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A, Neurology, vol.61, issue.7, pp.940-944, 2003. ,
DOI : 10.1212/01.WNL.0000086374.92906.6A
Respective potencies of Botox and Dysport : a double-blind, randomized, cross-over study in cervical dystonia, J Neurol Neurosurg Psychiatry, vol.72, pp.459-462, 2002. ,
SV2 Is the Protein Receptor for Botulinum Neurotoxin A, Science, vol.312, issue.5773, pp.592-598, 2006. ,
DOI : 10.1126/science.1123654
Mechanisms of pain in peripheral neuropathy, Acta Neurologica Scandinavica, vol.75, pp.12-24, 1999. ,
DOI : 10.1111/j.1600-0404.1999.tb07386.x
Touboul C Prevalence of chronic pain with neuropathic characteristics in the general population, Pain, 2007. ,
The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey, The Journal of Pain, vol.7, issue.4 ,
DOI : 10.1016/j.jpain.2005.11.008
The impact of neuropathic pain on health-related quality of life: Review and implications, Neurology, vol.68, issue.15, pp.1178-82, 2007. ,
DOI : 10.1212/01.wnl.0000259085.61898.9e
Health and Quality of Life Associated With Chronic Pain of Predominantly Neuropathic Origin in the Community, The Clinical Journal of Pain, vol.23, issue.2, pp.143-152, 2007. ,
DOI : 10.1097/01.ajp.0000210956.31997.89
Pharmacologic management of neuropathic pain: Evidence-based recommendations, Pain, vol.132, issue.3, pp.237-51, 2007. ,
DOI : 10.1016/j.pain.2007.08.033
Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study, British Journal of Dermatology, vol.50, issue.5, pp.986-89, 2007. ,
DOI : 10.1159/000076482